GLP-1 RA Drug NAION Cases: Possible Drug Injury Lawsuits
We are investigating possible drug injury lawsuits where people using glucagon-like peptide-I receptor agonist (GLP-1 RA) drugs were diagnosed with non-arteritic anterior ischemic optic neuropathy (NAION), resulting in vision loss or blindness. Those GLP-1 RA drug NAION cases involve these medications:
- Ozempic (semaglutide) – Novo Nordisk
- Wegovy (semaglutide) – Novo Nordisk
- Rybelsus (semaglutide) – Novo Nordisk
- Zepbound (tirzepatide) – Eli Lilly and Company
- Mounjaro (tirzepatide) – Eli Lilly and Company
These GLP-1 RA drug NAION cases would be filed against the responsible pharmaceutical companies as drug injury lawsuits.
A New NAION Side Effect Rate Number is Much Higher
An October 20, 2025, News Release from the American Academy of Ophthalmology, “Do GLP-1 Drugs like Ozempic Cause or Prevent Vision Loss?“, reports that a new study presented this week at the 129th annual meeting of the American Academy of Ophthalmology found a new, higher incident rate for GLP-1 RA drug NAION cases that involve semaglutide-containing drugs (Ozempic, Wegovy, and Rybelsus), but not tirzepatide-containing drugs (Zepbound and Mounjaro).
Researchers in an international collaboration across the University of Ottawa Eye Institute, University of Toronto, McMaster University, and Doheny Eye Institute UCLA conducted one of the largest global studies on the topic to date. Using data from the World Health Organization’s global database of drug safety reports, the authors analyzed data on 117,173 patients with diabetes taking semaglutide (GLP-1 drugs [Ozempic, Wegovy, Rybelsus]), empagliflozin, exenatide, tirzepatide [Zepbound and Mounjaro], or insulin.
Results showed that people using GLP-1 drugs were 68.6 times more likely to develop NAION and eight times more likely to develop diabetic retinopathy than those taking empagliflozin, exenatide, insulin or metformin. The analysis found no significant association between tirzepatide (the active ingredient in other GLP-1 medications including Mounjaro and Zepbound) and NAION or diabetic retinopathy.
The American Academy of Ophthalmology (AAO) is the world’s largest association of eye physicians and surgeons.
Vision Loss Lawsuits MDL Hearing in December 2025
Drug injury lawsuits filed for people using glucagon-like peptide-I receptor agonist (GLP-1 RA) drugs who were diagnosed with gastroparesis, gastric stasis, stomach paralysis, and other semaglutide-related stomach conditions are in this federal court MDL: IN RE: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION, MDL No. 3094.
The U.S. Judicial Panel on Multidistrict Litigation (JPML) will hear arguments in December 2025 on whether cases alleging that the use of glucagon-like peptide-I receptor agonist (GLP-1 RA) medications caused permanent vision loss should be consolidated with the cases in that federal court MDL involving gastrointestinal injuries, only, at present. This would include NAION cases that involve semaglutide-containing drugs (Ozempic, Wegovy, and Rybelsus) and tirzepatide-containing drugs (Zepbound and Mounjaro).
Related to this development is the fact that back in December 2024, the JPML decided that GLP-1 RA drug injury lawsuits involving blood clot-related injuries, such as deep vein thrombosis or pulmonary embolism, would not be part of the federal court MDL: IN RE: GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION, MDL No. 3094.
We will be watching for the JPML decision about whether GLP-1 RA drug NAION cases will be included in federal court MDL No. 3094 involving gastrointestinal injuries, or not.
Ozempic / Rybelsus / Wegovy
Free Case Evaluation
Strictly Confidential, No Obligation
Mounjaro / Zepbound
Free Case Evaluation
Strictly Confidential, No Obligation